Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in type 1 diabetes and T2D. 1 Type 1 diabetes, characterized by an inability to produce insulin because of autoimmunity, accounts for 5% to 10% of cases. 1 More than 90% to 95% of the diabetes population are classified as type 2 diabetes (T2D). The prevalence of diabetes has increased sharply in the United States over the past 4 decades with >34.2 million Americans with diabetes. Last, this scientific statement explores the critical importance of the social determinants of health and health equity in the continuum of care in diabetes and cardiovascular disease. This scientific statement addresses the continued importance of lifestyle interventions, pharmacological therapy, and surgical interventions to curb the epidemic of obesity and metabolic syndrome, important precursors of prediabetes, diabetes, and comorbid cardiovascular disease. This AHA scientific statement update focuses on (1) the evidence and clinical utility of newer antihyperglycemic agents in improving glycemic control and reducing cardiovascular events in diabetes (2) the impact of blood pressure control on cardiovascular events in diabetes and (3) the role of newer lipid-lowering therapies in comprehensive cardiovascular risk management in adults with diabetes. At present, several large randomized controlled trials with newer antihyperglycemic agents have been completed, demonstrating cardiovascular safety and reduction in cardiovascular outcomes, including cardiovascular death, myocardial infarction, stroke, and heart failure. At the time, there was limited evidence to suggest that glucose-lowering medications reduce the risk of cardiovascular events. The 2015 American Heart Association and American Diabetes Association scientific statement, “Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence,” highlighted the importance of modifying various risk factors responsible for cardiovascular disease in diabetes. Cardiovascular disease in diabetes is multifactorial, and control of the cardiovascular risk factors leads to substantial reductions in cardiovascular events. Customer Service and Ordering InformationĬardiovascular disease remains the leading cause of death in patients with diabetes.Stroke: Vascular and Interventional Neurology.Journal of the American Heart Association (JAHA).Circ: Cardiovascular Quality & Outcomes.Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB).
0 kommentar(er)
